• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » PhRMA Comes Out Against Additional Pediatric Trial Requirements

PhRMA Comes Out Against Additional Pediatric Trial Requirements

March 28, 2022

PhRMA has made clear it’s not in favor of any additional FDA requirements for pediatric trials of cancer drugs, at least for the time being, speaking out against policy changes during congressional testimony.

Stressing the importance of keeping incentives in place for developing rare disease drugs, Lucy Vereshchagina, vice president, science and regulatory advocacy for the industry trade group, called any changes or additions to pediatric cancer trial requirements “premature,” as relatively recently imposed requirements are assessed.

Specifically, the FDA Reauthorization Act of 2017 imposed new requirements that sponsors conduct pediatric trials of certain molecularly targeted cancer drugs if they’re evaluating them in adults and the drugs have the potential to address an unmet need in pediatric cancer patients. In conjunction, the legislation instructed the Government Accountability Office (GAO) to assess the effect of these requirements on drug development for pediatric cancer indications. With these provisions effective in August 2020, Vereshchagina contends there should be no new requirements until GAO issues its report in August 2023.

Vereshchagina’s comments could be in reference to legislation introduced by Reps. Michael McCaul (R-Tex.) and G.K. Butterfield (D-N.C.) that was discussed at a House Committee on Energy and Commerce health subcommittee hearing.

The legislation, which aims to help find treatments for relapsed pediatric cancers, would arm the FDA with the power to require trials that evaluate combinations of drugs. The lawmakers contend that although nearly all pediatric cancer trials involve children with relapsed cancer, the agency may currently only require pediatric cancer trials of single drugs, which rarely work for children whose cancers are advanced.

 

To view more CenterWatch Weekly stories, click here.

Upcoming Events

  • 12Apr

    The Patient Playbook Webinar Series, Part 3 — Rethinking the Development of Participant-Centric Clinical Trial Technology

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

  • White House

    Trial Stakeholders Advise White House on Emergency Research Infrastructure

  • SurveywBlueBackground-360x240.png

    Stress Levels Continue to Climb in Healthcare Workforce, Survey Finds

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing